{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:01:52Z","timestamp":1776913312362,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00702-022-02462-z","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:13:10Z","timestamp":1645477990000},"page":"715-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer\u2019s disease therapy"],"prefix":"10.1007","volume":"129","author":[{"given":"Moussa B. H.","family":"Youdim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1096\/fj.07-8627rev","volume":"22","author":"T Amit","year":"2008","unstructured":"Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S (2008) Targeting multiple Alzheimer\u2019s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22:1296\u20131305","journal-title":"FASEB J"},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0304-3940(89)90795-7","volume":"107","author":"K Arasaki","year":"1989","unstructured":"Arasaki K, Nakanishi T (1989) Selective neurotoxicity of clioquinol on the function of the posterior column nuclei. Neurosci Lett 107:85\u201388","journal-title":"Neurosci Lett"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1096\/fj.05-3794fje","volume":"19","author":"O Bar-Am","year":"2005","unstructured":"Bar-Am O, Weinreb O, Amit T, Youdim MB (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899\u20131901","journal-title":"FASEB J"},{"key":"2462_CR4","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1021\/bi020016x","volume":"41","author":"P Bar-On","year":"2002","unstructured":"Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I (2002) Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41:3555\u20133564","journal-title":"Biochemistry"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1021\/jm049782n","volume":"47","author":"ML Bolognesi","year":"2004","unstructured":"Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, Melchiorre C (2004) Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 47:5945\u20135952","journal-title":"J Med Chem"},{"key":"2462_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1527-3458.2003.tb00245.x","volume":"9","author":"U Bonnet","year":"2003","unstructured":"Bonnet U (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9:97\u2013140","journal-title":"CNS Drug Rev"},{"key":"2462_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.addr.2008.06.002","volume":"60","author":"M Bortolato","year":"2008","unstructured":"Bortolato M, Chen K, Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60:1527\u20131533","journal-title":"Adv Drug Deliv Rev"},{"key":"2462_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0091-3057(91)90183-3","volume":"39","author":"R Brandeis","year":"1991","unstructured":"Brandeis R, Sapir M, Kapon Y, Borelli G, Cadel S, Valsecchi B (1991) Improvement of cognitive function by MAO-B inhibitor l-deprenyl in aged rats. Pharmacol Biochem Behav 39:297\u2013304","journal-title":"Pharmacol Biochem Behav"},{"key":"2462_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347\u2013372","journal-title":"J Med Chem"},{"key":"2462_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.clinthera.2007.09.021","volume":"29","author":"JJ Chen","year":"2007","unstructured":"Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson\u2019s disease. Clin Ther 29:1825\u20131849","journal-title":"Clin Ther"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tox.2006.11.069","volume":"233","author":"EG Duysen","year":"2007","unstructured":"Duysen EG, Li B, Darvesh S, Lockridge O (2007) Sensitivity of butyrylcholinesterase knockout mice to (\u2013)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer\u2019s disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 233:60\u201369","journal-title":"Toxicology"},{"key":"2462_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/437942a","volume":"437","author":"S Frantz","year":"2005","unstructured":"Frantz S (2005) Drug discovery: playing dirty. Nature 437:942\u2013943","journal-title":"Nature"},{"key":"2462_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","volume":"95","author":"S Gal","year":"2005","unstructured":"Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95:79\u201388","journal-title":"J Neurochem"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1185\/03007990152673800","volume":"17","author":"NH Greig","year":"2001","unstructured":"Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK (2001) A new therapeutic target in Alzheimer\u2019s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17:159\u2013165","journal-title":"Curr Med Res Opin"},{"key":"2462_CR15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1124\/mol.107.033928","volume":"71","author":"E Groner","year":"2007","unstructured":"Groner E, Ashani Y, Schorer-Apelbaum D, Sterling J, Herzig Y, Weinstock M (2007) The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol Pharmacol 71:1610\u20131617","journal-title":"Mol Pharmacol"},{"key":"2462_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.sbi.2006.01.013","volume":"16","author":"AL Hopkins","year":"2006","unstructured":"Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16:127\u2013136","journal-title":"Curr Opin Struct Biol"},{"key":"2462_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","volume":"37","author":"D Kaur","year":"2003","unstructured":"Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson\u2019s disease. Neuron 37:899\u2013909","journal-title":"Neuron"},{"key":"2462_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.20672","volume":"59","author":"DE Kuhl","year":"2006","unstructured":"Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR (2006) In vivo butyrylcholinesterase activity is not increased in Alzheimer\u2019s disease synapses. Ann Neurol 59:13\u201322","journal-title":"Ann Neurol"},{"key":"2462_CR19","first-page":"527","volume":"3","author":"KC Lee","year":"2007","unstructured":"Lee KC, Chen JJ (2007) Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 3:527\u2013537","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2462_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2174\/138161209787315594","volume":"15","author":"R Morphy","year":"2009","unstructured":"Morphy R, Rankovic Z (2009) Designing multiple ligands\u2014medicinal chemistry strategies and challenges. Curr Pharm Des 15:587\u2013600","journal-title":"Curr Pharm Des"},{"key":"2462_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","volume":"60","author":"A Nunomura","year":"2001","unstructured":"Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759\u2013767","journal-title":"J Neuropathol Exp Neurol"},{"key":"2462_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/10837450500333179","volume":"10","author":"GA Patani","year":"2005","unstructured":"Patani GA, Pang YP, Chien YW (2005) A potent and selective tacrine analog\u2013biomembrane permeation and physicochemical characterization. Pharm Dev Technol 10:525\u2013538","journal-title":"Pharm Dev Technol"},{"key":"2462_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0014-5793(00)02323-1","volume":"486","author":"M Perez","year":"2000","unstructured":"Perez M, Cuadros R, Smith MA, Perry G, Avila J (2000) Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett 486:270\u2013274","journal-title":"FEBS Lett"},{"key":"2462_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0950-3536(89)80027-7","volume":"2","author":"JB Porter","year":"1989","unstructured":"Porter JB, Huehns ER (1989) The toxic effects of desferrioxamine. Baillieres Clin Haematol 2:459\u2013474","journal-title":"Baillieres Clin Haematol"},{"key":"2462_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","volume":"62","author":"J Saura","year":"1994","unstructured":"Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62:15\u201330","journal-title":"Neuroscience"},{"key":"2462_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/tx700210j","volume":"21","author":"LM Sayre","year":"2008","unstructured":"Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172\u2013188","journal-title":"Chem Res Toxicol"},{"key":"2462_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1176\/ajp.150.2.321","volume":"150","author":"LS Schneider","year":"1993","unstructured":"Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer\u2019s disease. Am J Psychiatry 150:321\u2013323","journal-title":"Am J Psychiatry"},{"key":"2462_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1196\/annals.1344.030","volume":"1053","author":"O Weinreb","year":"2005","unstructured":"Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann NY Acad Sci 1053:348\u2013355","journal-title":"Ann NY Acad Sci"},{"key":"2462_CR29","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.2741\/3069","volume":"13","author":"O Weinreb","year":"2008","unstructured":"Weinreb O, Amit T, Bar-Am O, Yogev-Falach M, Youdim MB (2008) The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci 13:5131\u20135137","journal-title":"Front Biosci"},{"key":"2462_CR30","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","volume":"20","author":"M Yogev-Falach","year":"2006","unstructured":"Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20:2177\u20132179","journal-title":"FASEB J"},{"key":"2462_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295\u2013309","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"2462_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nrn1537","volume":"5","author":"L Zecca","year":"2004","unstructured":"Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863\u2013873","journal-title":"Nat Rev Neurosci"},{"key":"2462_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"H Zheng","year":"2005","unstructured":"Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005a) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68\u201378","journal-title":"J Neurochem"},{"key":"2462_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","volume":"13","author":"H Zheng","year":"2005","unstructured":"Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M (2005b) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and other neurodegenerative diseases. Bioorg Med Chem 13:773\u2013783","journal-title":"Bioorg Med Chem"},{"key":"2462_CR35","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.bcp.2005.09.003","volume":"70","author":"H Zheng","year":"2005","unstructured":"Zheng H, Youdim MB, Weiner LM, Fridkin M (2005c) Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol 70:1642\u20131652","journal-title":"Biochem Pharmacol"},{"key":"2462_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1399-3011.2005.00289.x","volume":"66","author":"H Zheng","year":"2005","unstructured":"Zheng H, Youdim MB, Weiner LM, Fridkin M (2005d) Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res 66:190\u2013203","journal-title":"J Pept Res"},{"key":"2462_CR37","first-page":"4094","volume":"54","author":"H Zheng","year":"2009","unstructured":"Zheng H, Youdim MB, Fridkin M (2009) Site-Activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer\u2019s therapy. J Med Chem 54:4094\u20134098","journal-title":"J Med Chem"},{"key":"2462_CR38","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1096\/fj.07-8386com","volume":"21","author":"W Zhu","year":"2007","unstructured":"Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835\u20133844","journal-title":"FASEB J"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02462-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-022-02462-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02462-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T13:11:58Z","timestamp":1654953118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-022-02462-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":38,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1007\/s00702-022-02462-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}